COMPANY

Moonwalk Biosciences

HQ: South San Francisco, CA source · moonwalk.bio ↗

Keywords: RNA therapeutics siRNA metabolic obesity

Location: South San Francisco, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗

SEC Form D raise Raised $60M (Form D filed Sep 14, 2026). SEC Form D 0002004362-26-000003 (Sep 14, 2026)
Evidence (1 event)
- Sep 14, 2026 · SEC Form D 0002004362-26-000003
  Name of Issuer: Moonwalk Biosciences, Inc.; CIK: 2004362; Address: South San Francisco, CA; Submission type: D; Filing date: 2026-09-14; Industry Group: Biotechnology; Date of First Sale: 2026-08-26; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 70249973; Total Amount Sold: 59999998; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Raise Series B · $70M · announced Sep 8, 2026 Company release ↗
Source quote
- Sep 8, 2026 · Company release ↗
  “)- Moonwalk Biosciences , a biotechnology company developing first-in-class adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases, today announced the closing of an oversubscribed $70 million Series B financing”

Raises announced in these releases: $70M disclosed.

From the company’s own releases; this list is partial. All raises and deals